OMICS International Organises 3000+ Global Conferenceseries Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
For more Conferences visit www.conferenceseries.com

Back

Eman Medhat Hassan

Eman Medhat Hassan

Cairo University School of Medicine, Egypt

Title: Biobran/MGN-3, Arabinoxylan Rice Bran, for the Treatment of Chronic Hepatitis C

Biography

Prof Eman Medhat has completed her MD and postdoctoral studies from Cairo University School of Medicine. She is the director of a clinical hepatology unit, member of interventional ultrasound, HCC and ICU.units. She has published more than 40 papers in reputed journals and has been serving as an editorial board member of repute

Abstract

Hepatitis C virus (HCV) has infected about 185 million people worldwide and is a major cause of cirrhosis and hepatocellular carcinoma. Arabinoxylan Rice Bran (MGN-3/Biobran) is a natural product with proved strong immune-modulating effect. Based upon this effect, we examined its anti-HCV effect in patients with chronic HCV. Patients with chronic HCV (N=39) were randomized into two groups :The First group was treated with Biobran MGN group (1 g/day) (n=17) .and The Second,. Control group receiving standard treatment of PEG interferon plus ribavirin (n=22), PCR levels before treatment were compared to those after 3 and 6 months of treatment and patients in both groups showed significant reduction in the viral load relative to the baseline but there was no significant difference between both groups. As regards liver biochemical profile, there was significant improvement in ALT and AST levels in patients receiving MGN ,werewas not the case in control group. . Cost of 12-weeks treatments $10,000 for peg-interferon/ribavirin as compared to $300 for biobran, with minimal, if any adverse events and normal quality of life in the MGN group. Effects of the two regimens on the immune responses were studied. IFN-γ levels were significantly increased after 3 months of treatment when com pared to pretreatment serum levels in both groups ,bu tmore significant in MGN group P<0.05than in control one, There is significant changes were detected in CD3, CD,4markers in MGN group, however no significantchanges in the, CD14, CD16, CD19 or CD56 counts in both groups. We conclude that biobran is an immunomodulator ,may be therapeutic regimen that is safe and can be effective in treatment of chronic HCV patients.